This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Emergent Biosolutions (EBS) and Compass Therapeutics (CMPX)

Tipranks - Tipranks - Tue Jun 2, 5:32AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ionis Pharmaceuticals (IONS), Emergent Biosolutions (EBS) and Compass Therapeutics (CMPX) with bullish sentiments.

Claim 55% Off TipRanks

Ionis Pharmaceuticals (IONS)

In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Ionis Pharmaceuticals, with a price target of $125.00. The company’s shares closed last Friday at $76.50.

According to TipRanks.com, Kapoor is a 5-star analyst with an average return of 11.5% and a 43.8% success rate. Kapoor covers the Healthcare sector, focusing on stocks such as Kyverna Therapeutics, Inc., BioMarin Pharmaceutical, and Crispr Therapeutics AG. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ionis Pharmaceuticals with a $107.06 average price target, representing a 38.1% upside. In a report issued on May 20, Citi also initiated coverage with a Buy rating on the stock with a $90.00 price target.

See today’s best-performing stocks on TipRanks >>

Emergent Biosolutions (EBS)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Emergent Biosolutions, with a price target of $12.00. The company’s shares closed last Friday at $9.12.

According to TipRanks.com, Selvaraju is a 5-star analyst with an average return of 22.0% and a 55.5% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Santhera Pharmaceuticals Holding, MoonLake Immunotherapeutics, and Aardvark Therapeutics, Inc. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Emergent Biosolutions with a $12.00 average price target.

Compass Therapeutics (CMPX)

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Compass Therapeutics today and set a price target of $24.00. The company’s shares closed last Friday at $2.38.

According to TipRanks.com, Pantginis is a 5-star analyst with an average return of 21.2% and a 56.7% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Adlai Nortye Ltd. Sponsored ADR, Cadrenal Therapeutics, Inc., and NewAmsterdam Pharma Company. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Compass Therapeutics with a $10.11 average price target, representing a 316.0% upside. In a report issued on May 22, Canaccord Genuity also maintained a Buy rating on the stock with a $7.00 price target.

Read More on IONS:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).